DC
NTLA icon

Diametric Capital’s Intellia Therapeutics NTLA Stock Holding History

Diametric Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,553
Closed -$200K – 458
2025
Q3 		$200K Sell
11,553
-25,234
-69% -$311K 0.07% 332
2025
Q2 		$345K Sell
36,787
-8,639
-19% -$70.9K 0.18% 157
2025
Q1 		$323K Buy
+45,426
New +$459K 0.38% 89

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Diametric Capital's NTLA Position: Q4 2025 in Review

Diametric Capital sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 11,553 shares — an estimated $200K sold.

Diametric Capital first reported a position in NTLA in Q1 2025 and held it in 3 quarters. The position peaked at $345K in Q2 2025. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Diametric Capital reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Diametric Capital sold 11,553 Intellia Therapeutics shares in Q4 2025, an estimated $200K.
  • Diametric Capital first reported a position in Intellia Therapeutics in Q1 2025 and held it in 3 quarters.
  • Diametric Capital's Intellia Therapeutics position peaked at $345K in Q2 2025.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Diametric Capital's 13F filing for Q4 2025, filed 13 Feb 2026.